• Publications
  • Influence
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
TLDR
The analysis quantifies the enormity of the clinical and economic burdens of NAFLD, which will likely increase as the incidence ofNAFLD continues to rise. Expand
Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009
TLDR
NAFLD is becoming a major cause of HCC in the United States and is associated with shorter survival time, more advanced tumor stage, and lower possibility of receiving a LT. Expand
Strict versus liberal target range for perioperative glucose in patients undergoing coronary artery bypass grafting: a prospective randomized controlled trial.
TLDR
It was demonstrated that maintenance of blood glucose in a liberal range after coronary artery bypass grafting led to similar outcomes compared with a strict target range and was superior in glucose control and target range management. Expand
Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
TLDR
Treating all HCV patients with oral IFN-free regimen reduced the number of patients developing advanced liver disease and increased life expectancy, and IFN -free regimen without staging may be the most cost-effective approach for treating HCV genotype-1 patients. Expand
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
TLDR
Although advanced hepatic fibrosis is associated with HRQL and work productivity impairment, viral eradication with sofosbuvir+ledipasvir leads to HRQL improvement regardless of fibrosis stage. Expand
An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens
TLDR
The use of interferon- and RBV-free regimens for HCV is associated with better patients’ experience and work productivity during treatment. Expand
Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
TLDR
The use of interferon and/or RBV, longer duration of treatment, and lower baseline and on-treatment PRO scores were linked to a decreased likelihood of being adherent to interferOn + RBV-containing or interfer on-free RBV- containing antiviral regimens. Expand
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results
TLDR
The interferon- and ribavirin-free SOF/VEL regimen resulted in a rapid improvement of PROs in HCV GTs 2 and 3 patients during treatment and after achieving sustained virologic response. Expand
Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
TLDR
This placebo-controlled trial shows that patients treated with SOF/VEL experience significant improvement of their PROs during treatment and after achieving SVR, and is shown to improve health-related quality of life during treatment. Expand
Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).
TLDR
Treatment-related HRQL impairment during SOF and RBV regimen is mild, and does not increase with longer treatment duration, and achieving sustained virologic response after 12 weeks of follow-up with sofosbuvir andRBV was associated with improvement in HRQL scores from baseline. Expand
...
1
2
3
4
5
...